vTv Therapeutics Inc (NASDAQ:VTVT)

2.02
Delayed Data
As of 3:59pm ET
 -0.05 / -2.42%
Today’s Change
1.44
Today|||52-Week Range
4.75
+8.60%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$168.2M

Company Description

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Contact Information

vTv Therapeutics, Inc.
3980 Premier Drive
High Point North Carolina 27265
P:(336) 841-0300
Investor Relations:

Employees

Shareholders

Mutual fund holders4.81%
Other institutional3.16%
Individual stakeholders100.50%

Top Executives

Stephen L. HolcombePresident & Chief Executive Officer
Rudy C. HowardEVP, Chief Financial & Accounting Officer
Carmen ValcarceChief Scientific Officer & Executive VP
Aaron H. BursteinSenior Vice President-Clinical Development
Trey M. LambertSenior Vice President & General Counsel